Research into COVID-19
Call for papers: Impact of COVID-19 on clinical trials
Trials is inviting submission of manuscripts, long and short, including Letters and Commentaries detailing the enforced changes to trial design; trial management; recruitment; consent process; intervention delivery and follow up as a result of the COVID-19 pandemic. We also welcome submission of Updates to protocols previously published in Trials that describe changes made because of the COVID-19 pandemic. Please note that Trials will no longer be accepting submissions to this call for papers after 31st July 2022.Read More
Read the latest SARS-CoV-2 and COVID-19 research from Springer Nature
Springer Nature is committed to supporting the global response to emerging outbreaks by enabling fast and direct access to the latest available research, evidence and data.Read More
COVID-19 randomised trial protocols: rapid publication without barriers
Please note that the series COVID-19 randomised trial protocols: rapid publication without barriers, which opened 15th April 2020, with the Editorial of the same name, closed to new submissions on 15th July 2021.
Trials will continue to consider Study Protocol submissions via our standard workflow for research into COVID-19.